While very low-rely MBL hardly ever progresses to CLL, superior-count MBL progresses to CLL demanding therapy in a rate of one% to two% per annum. Superior-depend MBL is distinguished from Rai 0 CLL based on whether the B-cell depend is over or down below 5 × 109/L. Although men and women with each significant-count MBL and CLL Rai stage 0 are at